By staff writers

June 10, 2019 -- Turkish radiopharmaceutical developer Eczacibasi Monrol has entered the theranostics market with the introduction of Lutec (lutetium-177 chloride), a radiopharmaceutical precursor.

Lutec, which is compliant with European Pharmacopoeia standards, can be used to radiolabel carrier molecules for treating cancers such as neuroendocrine and prostate tumors, according to the firm. The company said it has 12 production facilities: five in Turkey and seven worldwide.

Copyright © 2019

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking